Janney Capital analyst Debjit Chattopadhyay raised his fair value estimate for bluebird bio shares to $125 from $81 citing the company's BCMA-targeted CAR-T data. After the presentation of updated results from a Phase 1 study of bb2121 in 18 patients with relapsed/refractory multiple myeloma, Chattopadhyay noted that responses are "deep and sustained," patients can be potentially retreated on relapse, CRS events are manageable and neurotoxicity has yet to manifest. Data from bluebird and Nanjing Legend leads the analyst to believe CAR-T therapies could rival autologous stem cell transplants in multiple myeloma, he tells investors. Chattopadhyay keeps a Buy rating on bluebird bio shares.